A groundbreaking advancement in cancer diagnostics has emerged from the Korea Institute of Materials Science (KIMS), introducing a plasmonic-based liquid biopsy platform that achieves ultrasensitive detection of KRAS mutations in early-stage colorectal cancer patients. This innovative technology leverages the unique optical properties of plasmonic nanomaterials combined with selective mutation amplification, enabling detection of trace mutant DNA within blood and urine samples with unprecedented precision.
Colorectal cancer, one of the predominant malignancies worldwide, often hinges on mutations in the KRAS gene that drive tumor growth. Traditional tissue biopsies, while informative, are invasive and challenging to perform repeatedly, particularly in early cancer stages. Liquid biopsies offer a minimally invasive alternative, analyzing circulating tumor DNA in bodily fluids; however, detecting mutations amid the overwhelming background of normal DNA requires exceptional sensitivity.
The KIMS team, led by researchers Minyoung Lee and Sunggyu Park, has addressed this challenge by merging plasmonic signal amplification with mutation-selective PCR amplification. This combined approach suppresses amplification of wild-type KRAS sequences while enhancing mutant DNA signals, drastically improving detection limits. Crucially, this platform demonstrated over 90% concordance in KRAS mutation status across matched tumor tissue, plasma, and urine specimens from patients with Stage 0 and Stage I colorectal cancer.
This remarkable sensitivity surpasses conventional PCR techniques and costly ultra-deep next-generation sequencing methods, promising a faster, more accessible diagnostic tool amenable to clinical workflows. Beyond blood, the inclusion of urine as a test specimen represents a significant leap forward in non-invasive cancer diagnostics, potentially reducing patient burden and enabling more frequent monitoring.
The implications of this technology extend well beyond early detection. It offers a powerful tool for companion diagnostics, treatment response assessment, and vigilant surveillance of minimal residual disease and cancer recurrence. Moreover, the platform’s adaptability to different cancers and genetic markers opens avenues for broad applications in precision oncology.
With the global liquid biopsy market rapidly expanding, this plasmonic-based system could complement existing NGS platforms, providing cost-effective mutation analysis with rapid turnaround times. KIMS plans to refine and extend the technology to other cancer types, including lung and pancreatic cancers, aiming to propel Korea’s biomedical industry onto the global stage.
“This study confirms the feasibility of urine-based mutation detection using plasmonic nanotechnology and sets the stage for a versatile diagnostic platform,” stated Minyoung Lee. Sunggyu Park emphasized continued innovation, “Integrating plasmonic materials with bio-diagnostics will revolutionize next-generation precision medicine platforms.”
Supported by Korean government initiatives, the research was published in the prestigious npj Precision Oncology journal, highlighting a pivotal step toward translating nanoscale materials science into life-saving medical technologies.
Subject of Research: Early detection of KRAS mutations in colorectal cancer using plasmonic-based liquid biopsy technology
Article Title: Translational feasibility of a plasmonic microarray–based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer
News Publication Date: May 2, 2026
Web References: http://dx.doi.org/10.1038/s41698-026-01452-8
Image Credits: Korea Institute of Materials Science (KIMS)
Keywords: plasmonic biosensor, liquid biopsy, KRAS mutation, colorectal cancer, early cancer detection, non-invasive diagnostics, precision oncology
